Floatz logo

Dexrazoxane

Acute Undifferentiated Leukemia

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Acute Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 3BB
DEXAMETHASONE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB

View all 50 →

Same molecule, other indications

Dexrazoxane is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
B
Indicative ·
59 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →